A. Graham Pockley, PhD

A. Graham Pockley, PhD is a distinguished scientist and entrepreneur with extensive experience in immunobiology and cancer research. He currently holds several key positions in the biotechnology industry and academia:

Professional Roles

Current Positions::

• CEO of multimmune GmbH in Munich, Germany (since October 2015)1
• Chief Scientific Officer and Member of Scientific Advisory Board at Radiance Biopharma Inc. in Boston, Massachusetts (since November 2023)1
• Chief Scientific Officer and Member of Scientific Advisory Board at ExoCellular Diagnostics Inc. in Boston, Massachusetts (since May 2023)1
• Chief Scientific Officer and Member of Scientific Advisory Board at Alphageneron Pharmaceuticals, Inc. in Boston, Massachusetts (since August 2021)1
• Emeritus Professor of Immunobiology at Nottingham Trent University, UK (since August 2022)13

Previous Positions::

• Director and Professor of Immunobiology at the John van Geest Cancer Research Centre, Nottingham Trent University (September 2016 - July 2022)1

Research Focus

Dr. Pockley's career has centered on:

• The immunobiology of disease
• Development of new immunotherapeutic strategies for aggressive and 'orphan' cancers
• Novel approaches for analyzing and interpreting complex datasets
• Defining new biomarkers of disease presence, status, and response to therapy in cancer patients1

Entrepreneurial Activities

In addition to his academic and industry roles, Dr. Pockley has demonstrated entrepreneurial spirit:

• He was the Founder and CEO of Chromocyte, a flow cytometry resource company (assets now sold to Biocompare)1

Academic Background

Dr. Pockley is an alumnus of St Bartholomew's Hospital, which celebrated its 900th anniversary in March 2023.2

His expertise and leadership in immunobiology have been recognized through his appointments at Nottingham Trent University, where he has made significant contributions to cancer research and education.4